Side-by-side IPO readiness, funding history, and valuation comparison. Data sourced by TechStackIPO.
Scores, valuations, and signals for Faire, Nimbus Therapeutics, and 370+ companies. 5-min read every Tuesday.
Faire is the wholesale marketplace connecting 700K+ independent retailers with 100K+ emerging brands — the B2B commerce platform for the indie retail economy. Valued at $12.4B with $1.7B raised, Faire processes billions in annual GMV and is the dominant wholesale marketplace globally. IPO candidate as B2B commerce digitisation continues to disrupt traditional wholesale distribution — a $50B+ global market.
| Industry | E-commerce |
| Stage | Series H |
| IPO Status | Private |
| Valuation | $12.4B |
| Total Funding | $1.7B |
| Headquarters | San Francisco, CA |
Nimbus Therapeutics uses structure-based drug design and computational tools to develop precision medicines for challenging targets including NASH, oncology, and immunology. Valued at $2B with $500M raised, Nimbus has multiple clinical-stage programs and partnerships with Takeda and Eli Lilly. Major healthtech IPO candidate as computational drug design matures into commercial medicine.
| Industry | Biotechnology |
| Stage | Late Stage Private |
| IPO Status | Private |
| Valuation | $2B |
| Total Funding | $637M |
| Headquarters | Cambridge, MA |
Complete funding history, cap table, S-1 analysis, and investor breakdown for any company. Instant PDF download.
Or buy any single company report for $19
Faire is valued at $12.4B. Nimbus Therapeutics is valued at $2B. Both figures are based on the most recent funding rounds tracked by TechStackIPO.
Faire filed an S-1 in April 2026 and is actively in the IPO pipeline. Nimbus Therapeutics is currently private. Track both companies on TechStackIPO for S-1 filings, roadshow announcements, and IPO date updates.
Faire has raised $1.7B. Nimbus Therapeutics has raised $637M.
Faire operates in E-commerce, while Nimbus Therapeutics operates in Biotechnology.
Faire is a E-commerce company valued at $12.4B with $1.7B raised. Nimbus Therapeutics is a Biotechnology company valued at $2B with $637M raised. See TechStackIPO's full side-by-side comparison for IPO readiness scores, funding timelines, and investor access options.
Accredited investors can access pre-IPO shares in Faire and Nimbus Therapeutics through secondary market platforms, pre-IPO funds, and broker-dealer platforms that facilitate private company transactions. TechStackIPO's marketplace section tracks available access options for both companies. Pre-IPO investments carry higher risk and limited liquidity.